Hindering Hazards: CluePoints CCO Talks to ICT About New Approaches in Trial Quality Maintenance – ICT
This article is taken from International Clinical Trials November 2017, pages 44-45. © Samedan Ltd.
The Role of Biostatistics in the Prevention, Detection, and Treatment of Fraud in Clinical Trials
By Marc Buyse, Stephen L. George, Stephen Evans, Nancy L. Geller, Jonas Ranstam, Bruno Sherrer, Emmanuel Lesaffre, Gordon Murray, Lutz Edler, Jane Hutton, Theodore Colton, Peter Lachenbruch and Babu L. Verma
Sequential Paclitaxel Followed by Tegafur and Uracil (UFT) or S-1 Versus UFT or S-1 Monotherapy as Adjuvant Chemotherapy for T4a/b Gastric Cancer (SAMIT): A Phase 3 Factorial Randomised Controlled Trial
By Akira Tsuburaya, Kazushiro Yoshida, Michiya Kobayashi, Shigefumi Yoshino, Masazumi Takahashi, Nobuhiro Takiguchi, Kazauki Tanabe, Naoto Takahashi, Hishori Imamura, Naokuni Tatsumoto, Akinori Hara, Kazuhiro Nishikawa, Ryoji Fukushima, Isao Nozaki, Hiroshi Kojima, Yumi Miyashita, Koji Oba, Marc Buyse, Satoshi Morita and Junichi Sakamoto